CC
NAUT icon

Casdin Capital’s Nautilus Biotechnolgy NAUT Stock Holding History

Casdin Capital’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-225,000
Closed -$1.38M – 55
2021
Q3 		$1.38M Sell
225,000
-275,000
-55% -$2.19M 0.03% 53
2021
Q2 		$5.05M Buy
+500,000
New +$5.42M 0.13% 49

Other funds holding NAUT

Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
AEPBI
AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Amazon.com Inc
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Casdin Capital's NAUT Position: Q4 2021 in Review

Casdin Capital sold out of Nautilus Biotechnolgy (NAUT) in Q4 2021, closing a stake of 225,000 shares — an estimated $1.38M sold.

Casdin Capital first reported a position in NAUT in Q2 2021 and held it in 2 quarters. The position peaked at $5.05M in Q2 2021. 81 funds tracked by Wall St. Rank hold NAUT as of Q4 2021.

  • Casdin Capital reported no remaining Nautilus Biotechnolgy position as of Q4 2021 after selling out during the quarter.
  • Casdin Capital sold 225,000 Nautilus Biotechnolgy shares in Q4 2021, an estimated $1.38M.
  • Casdin Capital first reported a position in Nautilus Biotechnolgy in Q2 2021 and held it in 2 quarters.
  • Casdin Capital's Nautilus Biotechnolgy position peaked at $5.05M in Q2 2021.
  • 81 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2021.

Based on Casdin Capital's 13F filing for Q4 2021, filed 14 Feb 2022.